Dr David L. Smith | Professor in the Department of Epidemiology
Johns Hopkins and the Center for Disease Dynamics

Dr David L. Smith, Professor in the Department of Epidemiology, Johns Hopkins and the Center for Disease Dynamics

David L Smith is a Professor in the Department of Epidemiology at Johns Hopkins University, the Johns Hopkins Bloomberg School of Public Health, and the Johns Hopkins Malaria Research Institute. He is also a Senior Fellow and Associate Director for Research at the Center for Disease Dynamics, Economics & Policy.  His research deals with the ecology, epidemiology, and economics of infectious diseases, the evolution of resistance to antibiotics and antimalarial drugs, and applied questions about infectious disease dynamics, control and intervention policy. His publications on malaria, flu, cholera, rabies, hospital-acquired infections, agricultural antibiotic use, and MRSA have appeared in top journals Science, Nature, The Lancet, Proceedings of the National Academy of Sciences USA, PLoS Biology, PLoS Medicine. Smith is a member of the Malaria Atlas Project (MAP), the Malaria Elimination Group (MEG), the Malaria Eradication Research Agenda (MalERA), and The Human Mobility Mapping Project (THUMMP). He consulted with the Zanzibar Minister of Health and the Zanzibar Malaria Control Progamme to write Malaria Elimination in Zanzibar, A Feasibility Assessment. His current research is funded by the Bill & Melinda Gates Foundation, the National Institutes of Allergies and Infectious Diseases, and the RAPIDD program of the Science & Technology Directorate, Department of Homeland Security, and the Fogarty International Center, National Institutes of Health.


DC Co-conference Day 2 April 4 @ 3:10

How can vaccines and vector control be integrated and used synergistically in a control program

·         Clinical development challenges associated with the design and conduct of emerging epidemic trials

·         Current status of Zika Vaccine candidates in Clinical Development

·         Geographical Considerations: Epidemiology v Trial Locations

·         Considerations for Zika Vaccine Clinical Development Strategy

back to speakers